Synthesis and Biological Evaluation of Hydroxylated Monocarbonyl Curcumin Derivatives as Potential Inducers of Neprilysin Activity

Background: Alzheimer’s disease (AD) involves impairment of Aβ clearance. Neprilysin (NEP) is the most efficient Aβ peptidase. Enhancement of the activity or expression of NEP may provide a prominent therapeutic strategy against AD. Aims: Ten hydroxylated monocarbonyl curcumin derivatives were designed, synthesized and evaluated for their NEP upregulating potential using sensitive fluorescence-based Aβ digestion and inhibition assays. Results: Compound 4 was the most active one, resulting in a 50% increase in Aβ cleavage activity. Cyclohexanone-bearing derivatives exhibited higher activity enhancement compared to their acetone counterparts. Inhibition experiments with the NEP-specific inhibitor thiorphan resulted in dramatic cleavage reduction. Conclusion: The increased Aβ cleavage activity and the ease of synthesis of 4 renders it an extremely attractive lead compound.


Introduction
For almost three decades, there has been an intensely growing and still unmet need to develop clinically successful therapeutics for the treatment of dementia and Alzheimer's disease (AD) [1]. Since 1992, when it was initially formulated [2], the amyloid cascade hypothesis has been driving the vast majority of therapeutic development in AD [3]. It postulates that the initial pathological event for AD neurodegeneration is the deposition of β-amyloid (Aβ). More specifically, abnormal accumulation of the peptides Aβ40 and Aβ42 can proceed via self-propagation into the aggregation of many different sizes, including soluble intermediate species (oligomers and protofibrils) and insoluble fibrils, which constitute the amyloid plaques. These species are associated with neuronal toxicity and synaptic dysfunction, eventually leading to neuronal death [4]. These peptides are derived either from enhanced amyloidogenic processing of the amyloid precursor protein (APP) or from declined clearance mechanisms. Consequently, Aβ neuronal loading could be reduced by fine-tuning the dynamic equilibrium between the peptide production and clearance. It is noteworthy that the failure of clearance mechanisms rather than the overproduction of the peptide appears to be the predominant cause of peptide accumulation in late-onset (sporadic) forms of the disease [5].
There are two distinct mechanisms primarily responsible for Aβ clearance. The first is the conveyance from the brain to the periphery with subsequent proteolytic removal and the second is the cerebral protease-mediated intra-and/or extracellular hydrolysis [6]. An overwhelming amount of evidence suggests the age-and pathology-related decrease in the expression or the activity of Aβ-degrading enzymes, such as the insulin-degrading enzyme (IDE) and neprilysin (NEP) [7]. More specifically, prodromal and early AD stages have been associated with low NEP levels, whereas an increased amount of Aβ was observed upon alterations in NEP expression [8][9][10]. Furthermore, synaptic plasticity and cognitive functions were significantly compromised in hAPP mouse models as a result of NEP inactivation [11]. Additionally, colocalisation of amyloid plaques with increased NEP levels was observed in transgenic Tg2576 Alzheimer-like mouse brain [12]. Finally, in a very recent report, the intravenous injections of a blood-brain barrier-permeable somatostatin-like peptide resulted in a significant increase in NEP levels, which was also accompanied by a significant and selective degradation of membrane-bound Aβ42 in the hippocampus [4]. Consequently, the upregulation of NEP can be considered a promising strategy against AD [13,14].
To this end, a variety of natural and synthetic molecules have been proposed as potential agonists aiming to increase either the expression levels or the hydrolytic function in in vitro or in vivo research protocols. For example, the thiourea NNC26-9100 ( Figure 1) decreased APP expression, resulting in the reduction in Aβ formation, and it inhibited the formation of Aβ42 trimers within both extracellular and intracellular cortical fractions [15,16]. The widely used histone deacetylase inhibitors, valproic acid and trichostatin A, exhibited significant ability to enhance the expression of NEP in SHSY-5Y cells, as well as in the cortex and hippocampus of rats [17,18]. Furthermore, 5-hydroxyindoleacetic acid (5-HIAA) caused upregulation of the levels of NEP in neuroblastoma cells and in vivo [19]. Estrogen, norepinephrine and testosterone induced elevation of NEP expression, leading to the amelioration of cognitive deficits in AD animal models [20]. With regard to natural products, EGCG strongly increased the NEP activity, thus leading to Aβ degradation [21], and resveratrol significantly increased both the estradiol and NEP level, thus decreasing Aβ deposition [22]. Finally, apigenin, luteolin and curcumin were able to induce specific NEP activity in SK-N-SH cells [23,24]. Recently, the work of Rita P-Y Chen and her group identified four curcuminoid compounds, the dihydroxylated curcumin, the monohydroxylated demethoxycurcumin, and the mono-and di-hydroxylated bisdemethoxycurcumin that have the ability to increase NEP activity [25]. Moreover, it has been found that curcumin has very poor solubility and bioavailability, whereas demethoxylation improves solubility and stability [26]. Herein, we would like to report the design, synthesis and biological evaluation of some hydroxylated monocarbonyl curcumin derivatives for the prevention and therapy of Alzheimer's disease through the upregulation of NEP-related activity. The potency of the compounds to induce NEP activity was evaluated by means of sensitive fluorescence-based Aβ digestion assays and inhibition assays.

General Procedure for Preparation of Compounds 1-4
Acetone (0.73 mL, 10 mmol) and concentrated hydrochloric acid (0.2 mL) were added to a suspension of 4-hydroxybenzaldehyde (2.44 g, 20 mmol) or vanillin (3.04 g, 20 mmol) in ethanol (3 mL). The reaction mixture was stirred at room temperature for 24 h. Upon completion of the reaction, the reaction mixture was concentrated under vacuum to half volume, poured into ice-cold water (40 mL), and 1% aqueous KOH solution was added until pH 6-7. Then, the precipitate was filtered and washed with water (×2) and hot water (×2) for 1 and 4 or only with water (<35 • C, ×2) for 2 and 3. Compound 3 was recrystallized from ethanol.

General Procedure for Preparation of Compounds 8-10
The appropriate intermediate 5-7 (0.5 mmol) and anhydrous DCM (10 mL) were added in a 50 mL two-necked round bottom flask under N 2 . The solution was cooled to -20 • C using ice/NaCl bath. Boron tribromide (2.5 mmol for 8 and 9, 3.5 mmol for 10) was injected carefully with a syringe. The reaction mixture was stirred for 1 h at −20 • C, then for 1 h at 0 • C and for 1 h at room temperature. Upon completion of the reaction, ice-cold water was poured into the mixture, and the flask was shaken for a few minutes. The resulting precipitate was filtered and washed with small amounts of water. An additional amount of product was recovered from the filtrate after extraction with EtOAc.

Preparation of Compound 12
p-Anisaldehyde (1.33 g, 9.7 mmol) and ketone 11 in EtOH (2 mL) were added dropwise to a solution of NaOH (0.78 g, 19.4 mmol) in EtOH (14 mL) and water (14 mL). After stirring for 16 h at room temperature, a beige oil was formed. After separation of the oily product from the upper layer, HCl 1M and EtOAc were added, and the two phases were separated. The aqueous layer was extracted two more times with EtOAc. The organic extract was washed with HCl 1M (×2) and brine, and then dried with NaSO 4 and concentrated in vacuo to give an orange coloured oil. The yellow coloured pure product was isolated by flash chromatography (DCM to DCM:EtOAc = 8/2).

Preparation of Compound 13
Intermediate compound 12 (162 mg, 0.5 mmol) and anhydrous DCM (10 mL) were added in a 50 mL two-necked round bottom flask under N 2 . The solution was cooled to -20 • C using ice/NaCl bath. Boron tribromide (2.0 mmol) was injected carefully with a syringe. The reaction mixture was stirred for 1 h at −20 • C, then for 1 h at 0 • C and 1 h at room temperature. Upon completion of the reaction, ice-cold water was poured into the mixture, and the flask was shaken for a few minutes. The mixture was extracted with Et 2 O (×3). Then, the combined organic extracts were extracted with a 10% aqueous solution of NaOH. The aqueous solution was acidified with an aqueous solution of HCl 10% until pH 5 and then extracted again with Et 2 O (×3). The organic extracts were dried with Na 2 SO 4 and concentrated in vacuo to give an oily crude product. The final product was isolated by flash chromatography (DCM:MeOH = 98/2 to 90/10) as a dark green powder.

Preparation of Compound 14
Dry K 2 CO 3 (11 g, 75 mmol), 3,4-dihydroxybenzaldehyde (2 g, 15 mmol) and dry DMF (15 mL) were added in a round bottom flask under argon. Methoxymethylchloride (4.5 mL, 60 mmol) was added dropwise over 2 h. The reaction mixture was then stirred vigorously for 16 h at room temperature. Upon completion of the reaction, the solvent was evaporated to dryness. After addition of water, the mixture was extracted with CHCl 3 (×3). The combined extracts were washed with HCl 1M (×2), brine, dried with Na 2 SO 4 and concentrated to give a beige-coloured oil. The pure product was isolated by flash chromatography (n-hexane:EtOAc = 8/2) as a white solid.

Preparation of Compound 17
Compound 16 was prepared by reacting aldehyde 14 with ketone 15 similarly as described above for 12 (product was isolated by flash chromatography, n-hexane:EtOAc = 6/4). Compound 16 (160 mg, 0.4 mmol) was dissolved in MeOH (5 mL). After dropwise addition of 3 M HCl, the mixture was stirred at 65 • C for 2 h. Upon completion of the reaction, the methanol was evaporated. After extraction of the mixture with EtOAc (×3), the combined organic extracts were washed with brine, dried with Na 2 SO 4 and concentrated to give a brown-coloured oil. The pure product was isolated by column chromatography (CHCl 3 :MeOH = 9/1) as a bright yellow solid. [36] Yield: 56 mg (45%), 1

Synthesis of Compound 19
Compound 19 was prepared similarly as described above for 8-10. A quantity of 2.0 mmoles of BBr 3 was used and, during the work-up, after shaking the reaction mixture with water, it was extracted with EtOAc (×3). The organic extracts were dried with Na 2 SO 4 and the final product was isolated as yellow solid by flash chromatography (DCM:MeOH = 95/5).

Synthesis of qf-Aβ(1-7)C
The protocol of qf-Aβ(1-7)C synthesis was modified from a previous protocol [37]. The peptide Aβ(1-7)C (sequence DAEFRHDC, which corresponds to residues 1 to 7 of the Aβ peptide followed by a cysteine residue), was prepared by the Fmoc-polyamide method on a PS3 peptide synthesizer (Rainin Instrument Co., Inc.; Woburn, MA, USA). Then, 1/20 volume of N-methylmorpholine (NMM) was added to achieve a mild basic condition. The mixture was reacted with gentle inversion for 2 h at room temperature in the dark. After the reaction, the reaction mixture was centrifuged at 19,000 g at 4 • C for 15 min. The supernatant was collected and the double-labeled peptide in the supernatant, designated qf-Aβ(1-7)C, was purified by HPLC, identified on a MALDI mass spectrometer, lyophilised, and stored at −20 • C.

Synthesis of qf-Aβ(12-16)AAC-EDANS
The protocol of qf-Aβ(12-16)AAC synthesis was modified from a previous protocol [38]. The Aβ(12-16)AAC (sequence VHHQKAAC, which corresponds to residues 12 to 16 of the Aβ peptide followed by two alanine residues and one cysteine residue) was synthesised on a PS3 peptide synthesiser. The thiol-reactive EDANS C2 maleimide was used as the fluorescence donor instead of Alexa-350. Tris (2-carboxyethyl) phosphine (TCEP) was dissolved in DMSO to make a 50 mM stock solution. About 5 mg of crude Aβ(12-16)AAC in 850 µL of 200 mM MOPS buffer (pH 7.2) and 1 mg of EDANS in 100 µL of DMSO were mixed with 50 µL of TCEP stock solution. The molar ratio of peptide:dye is 2:1. The mixture was reacted at room temperature in the dark overnight with gentle inversion (91 rpm). The EDANS-labeled Aβ(12-16)AAC was purified by HPLC and identified on a MALDI mass spectrometer. EDANS-labeled Aβ(12-16)AAC was lyophilised, re-dissolved in DMSO, and mixed with Dabcyl. The molar ratio of peptide and Dabcyl is 1:10. To the mixture, 1/20 volume NMM was added in and reacted with gentle inversion for 2 h at room temperature in dark. After the reaction, the reaction mixture was centrifuged at 19,000 g at 4 • C for 15 min. The supernatant was collected and the double-labeled peptide, designated qf-Aβ(12-16)AAC-EDANS, was purified by HPLC, identified on a MALDI mass spectrometer, lyophilised, and stored at −20 • C.

Statistical Analysis
All the experiments were repeated three times and, each time, the process was performed in triplicate. The average intensity of three experiments was normalised to the control group. All statistical analyses were performed using GraphPad Prism 8 software (Graphpad). Statistical significances were compared with the control group and determined by one-way ANOVA with Dunnett's multiple comparisons test (*, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001). Data are expressed as mean value ± SD.
Interventionary studies involving animals or humans, and other studies that require ethical approval, must list the authority that provided approval and the corresponding ethical approval code.

Design
As part of an effort to develop improved curcuminoids, the design of monocarbonyl analogs of curcumin (MACs) as a highly attractive alternative class of compounds was chosen [27][28][29]. MACs usually demonstrate higher potency than the diketo-curcuminoid counterparts, they are more readily produced, more stable, and they exhibit improved pharmacological profiles [39,40]. Based on the above, a small library of symmetric and unsymmetric hydroxylated monocarbonyl curcumin derivatives was designed using acetone or cyclohexanone as linkers between the aromatic moieties ( Figure 2). Some of these compounds are indeed the monocarbonyl analogues of the most active diketo curcuminoids previously reported [25].

Synthesis
The target compounds were synthesized following five different routes depending on their structure. Thus, symmetric compounds 1-4 were prepared by a conventional Claisen-Schmidt reaction from the corresponding aromatic aldehydes and acetone or cyclohexanone, by using a catalytic amount of concentrated hydrochloric acid (Scheme 1). In a similar approach, symmetric compounds 8-10 were synthesized from the methoxyprotected intermediates 5-7, prepared from the corresponding aromatic aldehydes and acetone or cyclohexanone, in alkaline conditions (Scheme 2) [28]. It is worth noting that the Claisen-Schmidt condensation of the unprotected aldehyde coupling partners did not proceed well in these conditions. However, the commercial availability of the starting materials, and the deprotection of the intermediates 5-7, following a boron tribromide protocol, ensured an efficient two-step route to the target compounds 8-10.
Synthesis of the unsymmetrical compound 13 proceeded via the "half" derivative 11, prepared from veratraldehyde, using a large excess of acetone, in order to achieve monoderivatization at this step (Scheme 3). Further condensation of 11 with p-anisaldehyde afforded the protected unsymmetric intermediate 12, following a slightly modified Claisen-Schmidt in comparison to the protocol used for 5-7. Treatment of 12 with boron tribromide, afforded the target compound 13, in 65.4% overall yield from the starting aldehyde. For the synthesis of the unsymmetrical compound 17, which bears hydroxyl groups and a methoxy group, an orthogonal protection strategy was required (Scheme 4). Therefore, starting from the commercially available 3,4-dihydroxybenzaldehyde and vanillin, we first prepared the MOM-protected aldehyde 14 and ketone 15, respectively. The latter compounds were condensed via a Claisen-Schmidt reaction to afford the partially MOMprotected intermediate 16, which was selectively deprotected under acidic conditions to afford the target compound 17. Finally, the target compound 19 was prepared from 3,4,5-trimethoxybenzaldehyde, after condensation with acetone to afford the "half" derivative 18, which was subsequently deprotected by using boron tribromide (Scheme 5).

Synthesis and Specificity of Fluorescent Peptide NEP Substrates
The effect of the hydroxyl-bearing monocarbonyl compounds on the neprilysin Aβdegrading activity was evaluated by means of a fluorescence-based Aβ digestion assay. For this purpose, the qf-Aβ(1-7)C and the qf-Aβ(12-16)AAC-EDANS peptides were successfully synthesized based on previous work with slight modifications to increase yield [37,38].
These peptide substrates are designed to carry both a fluorescence reporter and a quencher onto them. In the case of Aβ(1-7)C, Alexa-350 was used as a fluorescent moiety whereas this was replaced by a more economical and chemically attractive fluorescent reporter, the 5-[(2-Aminoethyl)amino]naphthalene-1-sulfonyl (EDANS), in the case of qf-Aβ(12-16)AAC substrate. Both fluorescent peptides were conjugated to Dabcyl as the quencher. Among the Aβ-degrading enzymes including NEP, ECE-1, ACE, IDE, plasmin, NMP-3 and NMP-9, qf-Aβ(1-7)C is sensitive to NEP and IDE (insulin-degrading enzyme) degradation only [37]. On the other hand, qf-Aβ(12-16)AAC is more susceptible to NEP and ACE (angiotensin converting enzyme) [38]. Based on our previous experience, it was initially important to assure that NEP is still able to effectively cleave qf-Aβ(12-16)AAC-EDANS and its selectivity has not been altered by changing the fluorophore.
The ability of NEP to degrade the newly prepared peptide qf-Aβ(12-16)AAC-EDANS was evaluated by means of fluorescence spectroscopy. A minute amount of NEP (2 nM) was used in the appropriate buffer and then, upon incubation with the peptide for various time intervals, the fluorescent spectrum was recorded ( Figure 3A). There is a significant increase in the fluorescence intensity observed with longer incubation time, which clearly indicates the effective and desirable NEP-assisted cleavage of the peptide. It should be mentioned that no fluorescence was recorded in the absence of NEP, which means that the peptide was completely stable in the buffer used and that the recorded increasing intensity was exclusively the result of Aβ(12-16)AAC cleavage. Furthermore, qf-Aβ(12-16)AAC-EDANS was equally challenged by the same amount of NEP, IDE and ACE to evaluate the substrate specificity. The results presented in Figure 3B demonstrate that qf-Aβ(12-16)AAC-EDANS retains its selectivity as a substrate to ACE and NEP, as was also the case for qf-Aβ(12-16)AAC, which was used in previous works in a comparable way [38].

NEP Aβ-Degrading Activity in Cells and Inhibition Studies
Subsequently, the Aβ-degrading activity in SH-SY5Y cells was evaluated by using either qf-Aβ(1-7)C or qf-Aβ(12-16)AAC-EDANS as substrate with or without the tested compounds. The cell viability of SH-SY5Y cells was not affected by the compounds at the 5 µM concentration that was used to assess NEP activity. The results presented in Table 1 and Figure 4 show that compounds 1, 2, 3, 4, and 8 exhibited a significant fluorescence increase in both assays, whereas compounds 9, 10, 17 and 19 exhibited a statistically significant increase in one of the two assays. More specifically, compound 4 was the most active in the qf-Aβ(1-7)C assay whereas derivatives 17 and 19 were of the highest activity in the qf-Aβ(12-16)AAC-EDANS assay. Furthermore, most of the compounds had higher activity increases in the qf-Aβ(1-7)C assay than the qf-Aβ(12-16)AAC-EDANS, except for compounds 10, 17, and 19. These results may be influenced by the fact that NEP is not the only catabolizing enzyme involved; qf-Aβ(1-7)C may also be successfully cleaved by IDE [37], and qf-Aβ(12-16)AAC-EDANS is, similarly, a good substrate for ACE [38]. Thiorphan, a NEP-specific inhibitor was, therefore, used to selectively block the activity of NEP and record any remaining fluorescent intensity presumably resulting from IDE or ACE cleavage, respectively. Table 1. Comparison of Aβ-degrading activity by using qf-Aβ(1-7)C or qf-Aβ(12-16)AAC-EDANS. CURCU-8 is 1,7-Bis(3,4dihydroxyphenyl)-1,6-heptadiene-3,5-dione. a Data retrieved from the previous report [25].  After incubating SH-SY5Y cells with or without compound 4, the cells were treated with 50 µM thiorphan prior to addition of qf-Aβ(1-7)C. The same experimental procedure was followed with compound 19 and qf-Aβ(12-16)AAC-EDANS. In both cases, thiorphan was found to significantly decrease substrate cleavage activity to more than 50% of the untreated control, as shown in Figure 5. More specifically, in the case of qf-Aβ(1-7)C substrate, thiorphan reduced the compound 4 related fluorescence increase by nearly 70% and there was no statistically significant difference compared to the control. This result strongly demonstrates that the increased activity induced by compounds 4 was almost exclusively due to its effect on NEP. Interestingly, the thiorphan treatment resulted in a small residual fluorescence compared to the control when qf-Aβ(12-16)AAC-EDANS substrate was used, in the presence or absence of compound 19. This observation not only indicates that the fluorescence increase caused by compound 19 may be related to NEP activation but also, to some extent, that ACE activation may be involved. Figure 5. Thiorphan inhibition assay. SH-SY5Y cells were incubated for 12 h in the presence or not of compound 4 or 19 (5 µM), followed by thiorphan (50 µM) for 30 min before Aβ-degrading activity was measured using the appropriate substrate. The data are the mean ± SD for three independent samples. * p < 0.05; *** p < 0.001; ****, p < 0.0001 compared to the control by one-way ANOVA.
With regard to the qf-Aβ(1-7)C assay, it is noteworthy that for the mono-or disubstituted symmetric compounds 1-9, the cyclohexanone derivatives were found to be more active than the corresponding acetone derivatives. In addition, derivative 2 exhibited higher activity than its diketo counterpart; specifically, curcumin and compound 8 was only slightly less active than the di-hydroxylated bisdemethoxycurcumin [25]. Moreover, their cyclohexanone analogues 4 and 9 were found to increase NEP activity even more. On the other hand, the tri-substituted derivatives 10 and 19, and the unsymmetrical 13 and 17, resulted in a non-statistically significant increase in activity compared to the control. Interestingly, the activity increase did not seem to be related to the number of hydroxyl groups. In fact, compound 10, which has 6 hydroxyl groups, did not cause a significant activity increase in the qf-Aβ(1-7)C assay and exhibited the lowest % increase in all tested compounds. Consequently, the results of this work do not seem to provide further support to previous observations on diketo curcuminoids, where at least three hydroxyl groups were required for neprilysin upregulation [25]. Collectively, the two sets of results indicate that it is not only the degree of hydroxylation that is the main predominant factor affecting the potential NEP activity enhancement. In the case of diketo curcuminoids, the enhanced solubility of the polyhydroxylated derivatives may have provided the activity benefit observed. However, for the monocarbonyl analogues, which are known to have superior aqueous solubility and stability compared to their diketo counterparts [40,41], the activity was affected in a different way. Our results suggest that balancing the phenolic character with vanillin-based aromatic motif and the more rigid and bulky cyclohexanone moiety resulted in the highest activity for compound 4 in the qf-Aβ(1-7)C assay. It is also worth mentioning that the ease of preparation and purification, as well as the lower synthetic cost, of this compound in multigram scale from simple starting materials, makes it a highly desirable pharmaceutical candidate.
Our results demonstrate a very highly promising role of the monocarbonyl curcumin derivatives as proteolytic potentiation agents via NEP. From a mechanistic point of view, the increased proteolysis has been previously suggested to be related to promoted expression, secretion and (allosterically) catalytic activation of the targeted endopeptidase as well as epigenetic regulation at the level of histones [20]. More specifically, the histone deacetylase (HDAC) inhibitors, such as valproic acid and trichostatin, have been related to reactivated NEP gene expression via blocking of the competitive binding of HDACs to the NEP promoter [17]. Curcumin and a small library of diketone curcumin analogues have been shown to act as promising HDAC inhibitors [42]. Furthermore, PPARγ agonists have also been shown to induce Aβ degradation by increasing apolipoprotein E (ApoE), which has been shown to cause an increase in the concentration of NEP [43,44]. To this end, curcumin may act as a potent PPAR gamma agonist resulting in the inhibition of Abeta-induced inflammation in astrocytes [45]. In addition, NEP activity has been found to be reduced in the presence of Aβ-generated reactive oxygen species (ROS) [46]. In that respect, the work of Zheng et al. reported superior anti-oxidant activity for monocarbonyl curcumin derivatives, including some of our tested compounds [47]. This may contribute, at least partially, to the NEP activity enhancement observed herein. There is no similar report and comparative study for any of the other NEP regulating pathways described earlier. Finally, there is not a well-defined structure-activity-relationship profile for small molecules able to enhance the catalytic activity (or production) of such proteases. Consequently, further elucidation of the specific mode of action of the successful derivatives is underway.

Conclusions
Ten hydroxylated monocarbonyl curcumin derivatives were successfully synthesized and evaluated for their potential to enhance the activity of NEP in fluorescence-based Aβ digestion and inhibition assays. The cyclohexanone-bearing vanillin derivative resulted in a highly significant increase in NEP activity. This molecule can be readily prepared at large scale, high purity and low cost. Our extremely encouraging set of results prompts us to further exploit the potential application of this molecule against AD.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10 .3390/biomedicines9080955/s1, Tables S1-S22 1 H, 13 C and 2D NMR spectra. Funding: This research was funded by the project "An Open-Access Research Infrastructure of Chemical Biology and Target-Based Screening Technologies for Human and Animal Health, Agriculture and the Environment (OPENSCREEN-GR)" (MIS 5002691), which is implemented under the Action "Reinforcement of the Research and Innovation Infrastructure", funded by the Operational Programme "Competitiveness, Entrepreneurship and Innovation" (NSRF 2014-2020) and co-financed by Greece and the European Union (European Regional Development Fund).

Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.

Data Availability Statement:
The data presented in this study are available in this article and Supplementary Materials.